Business & Finance Buy this biotech stock on pivot to immune disease treatments, Wells Fargo says
The bank's research arm raised its rating on the stock to overweight from equal weight.
By
· April 20, 2026 · 1 min read
This article was originally published by
CNBC Top News
and is republished here under license.
The bank’s research arm raised its rating on the stock to overweight from equal weight.
Like this:
Like Loading...
Related
The Iran war wasn't the only focus. Corporate earnings and a split between hardware and software stocks caught our attention…
By
· April 25, 2026 · 1 min read
President said he was no longer sending Steve Witkoff and Jared Kushner to Pakistan…
By
· April 25, 2026 · 1 min read
…
By
· April 25, 2026 · 1 min read
Leave a Reply